DELIVERY ORDER
Active75A50126F61014
Department of Health and Human Services › Office of Assistant Secretary for Preparedness and Response › BARDA - ASPR / DAAPPO / BARDA DCMA
$2.1M
obligated · signed 2 months ago
MANUFACTURE AND STABILITY STUDIES OF THIMEROSAL-FREE PANDEMIC INFLUENZA VACCINE MULTIDOSE VIALS (MDVS)
Performance timeline
Start
Sep 30, 2026
Current end
Sep 29, 2028
Potential end
Sep 29, 2029
with all options
Loading status
Estimated start: Sep 29, 2028
SEQIRUS INC
Contract 75A50126F61014
UEI
Z6N1LJ2RD6E3
Parent Company
SEQIRUS INC
Capabilities & Certifications
Headquarters Location
Congressional District: 04
Current Obligation
$2,148,912
Base + Exercised Options
$2,148,912
Total Ceiling Value
$28,689,803
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING
PSC
DRUGS AND BIOLOGICALS
Place of Performance
Congressional District: 13
Awarding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Funding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Contract Vehicle
75A50122D00004
IDCDepartment of Health and Human Services
Award type: SINGLE AWARD
Solicitation procedures, competition exceptions, labor standards and account totals.